Current management of non-muscle-invasive bladder cancer

Minerva Medica

Volumn 104, Issue 3, 2013, Pages 273-286

  Rodriguez Faba, O ^a   Gaya, J M ^a   Lopez J M ^a   Capell, M ^a   De Gracia Nieto, A E ^a   Gomez Correa E ^a   Breda, A ^a   Palou, J ^a  

^a FUNDACIÓ PUIGVERT   (Spain)

Author keywords

Comorbidity; Transurethral resection of prostate; Urinary bladder neoplasms

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; AURORA A KINASE; BCG VACCINE; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CORTICOSTEROID; CYTOKERATIN 20; EPIRUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYALURONIC ACID; HYALURONIDASE; ISONIAZID; KI 67 ANTIGEN; MITOMYCIN; POLO LIKE KINASE 1; PREDNISOLONE; PROTEIN BLCA1; PROTEIN BLCA4; PROTEIN P53; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SURVIVIN; TETRACAINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABSCESS DRAINAGE; ARTHRALGIA; ARTHRITIS; ARTICLE; BACTERIAL INFECTION; BLUE LIGHT; BLUE LIGHT CYSTOSCOPY; CANCER ADJUVANT THERAPY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER THERAPY; CARCINOMA IN SITU; CHILL; CONSERVATIVE TREATMENT; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DRUG INSTILLATION; DRUG MEGADOSE; ECHOGRAPHY; EPIDIDYMITIS; EPIDIDYMOORCHITIS; FEVER; FOLLOW UP; GENE MUTATION; HEMATURIA; HEPATITIS; HIGH RISK PATIENT; HUMAN; IRRITATIVE VOIDING SYNDROME; LABORATORY DEVICE; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDLINE; META ANALYSIS (TOPIC); MICROSATELLITE MARKER; MINIMAL RESIDUAL DISEASE; NON MUSCLE INVASIVE BLADDER CANCER; ORCHITIS; PENIS DISEASE; PNEUMONIA; PREDICTIVE VALUE; PROSTATITIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REOPERATION; SENSITIVITY AND SPECIFICITY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSURETHRAL RESECTION; TUBERCULOSIS; TUBERCULOUS ARTHRITIS; ULCER; URINARY TRACT INFECTION; WHITE LIGHT CYSTOSCOPY; WHITE LIGHT ENDOSCOPY;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK; URINARY BLADDER NEOPLASMS;

EID: 84882394659     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008;218:12-20.
4. Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young patients. J Urol 1998;159:1493-6.
5. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl 2008;218:64-78.
6. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
7. Dryson E, Mannetje A, Walls C, McLean D, McKenzie F, Maule M et al. Case-control study of high risk occupations for bladder cancer in New Zealand. Int J Cancer 2008;122:1340-6.
8. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control sUidies. Int J Cancer 2000;86:289-94.
9. Balbi JC, Larrinaga MT, De Stefani E, Mendilaharsu M, Ronco AL, Boffetta P et al. Foods and risk of bladder cancer: a case-control study in Uruguay. Eur J Cancer Prev 2001;10:453-8.
10. Brinkman M, Zeegers MP. Nutrition, total fluid and bladder cancer. Scand J Urol Nephrol Suppl 2008;218:25-36.
11. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.
12. Abol-Enein H. Infection: is it a cause of bladder cancer? Scand J Urol Nephrol Suppl 2008;218:79-84.
13. Boice JD Jr, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988;116:3-55.
14. Nilsson S, Ullen A. Chemotherapy-induced bladder cancer. Scand J Urol Nephrol Suppl 2008;218:89-92.
15. Malone PR, Weston-Underwood J, Aron PM, Wilkinson KW, Joseph AE, Riddle PR. The use of transabdominal ultrasound in the detection of early bladder tumours. Br J Urol 1986;58:520-2.
16. Davies AH, Cranston D, Meagher T, Fellows GJ. Detection of recurrent bladder tumours by transrectal and abdominal ultrasound compared with cystoscopy. Br J Urol 1989;64:409-11.
17. Vallancien G, Veillon B, Charton M, Brisset JM. Can transabdominal ultrasonography of the bladder replace cystoscopy in the followup of superficial bladder tumors? J Urol 1986;136:32-4.
18. Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl 1995;172:33-6.
19. Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002;168:978-80.
20. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31 A: 1840-6.
21. Dalbagni G, Rechtschaffen T, Herr HW. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? J Urol 1999;162(3 Pt 1):708-9.
22. Tomasini JM, Konety BR. Urinary markers/cytology: what and when should a urologist use. Urol Clin North Am 2013;40:165-73.
23. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2008;53:909-l6.
24. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010;14:1-331, iii-iv.
25. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J et al., European Association of U: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
26. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;26:646-51.
27. Schmitz-Drager BJ, Beiche B, Tirsar LA, Schmitz-Drager C, Bismarck E, Ebert T. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 2007;51:1582-8; discussion 1588.
28. Babjuk M, Soukup V, Pesl M, Kostirova M, Drncova E, Smolova H et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapTl bladder urothelial carcinoma. Urology 2008;71:718-22.
29. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011;60:484-92.
30. Jocham D, Witjes F, Wagner S, Zeylemaker B, Van Moorselaar J, Grimm MO et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862-6; discussion 866.
31. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010;57:595-606.
32. Burgues JP, Conde G, Oliva J, Abascal JM, Iborra I, Puertas M et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group]. Actas Urol Esp 2011;35:439-45.
33. Brausi M, Collette L, Kurth K, Van Der Meijden AP, Oosterlinck W, Witjes JA et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta Tl transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523-31.
34. Badalato G, Patel T, Hruby G, McKiernan J. Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cTl bladder cancer? BJU Int 2011;108:1292-6.
35. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007;178(4 Pt 1):1201-5; discussion 1205.
36. Jahnson S, Wiklund F, Duchek M, Mestad O, Rintala E, Hellsten S et al. Results of second-look resection after primary resection of Tl tumour of the urinary bladder. Scand J Urol Nephrol 2005;39:206-10.
37. Gaya JM, Palou J, Cosentino M, Patino D, Rodriguez-Faba O, Villavicencio H. [A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]. Actas Urol Esp 2012;36:539-44.
38. Holmang S. High-grade non-muscle-invasive bladder cancer: Is re-resection necessary in all patients before intravesical bacillus Calmette-Guerin treatment? Scand J Urol 2013 [Epub ahead of print].
39. Van Der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, De Balincourt C. Significance of bladder biopsies in Ta, Tl bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999;35:267-71.
40. Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 2012;62:118-25.
41. Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005;48:53-9; discussion 59.
42. Sylvester RJ, Van Der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta Tl bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49(3):466-465; discussion 475-467.
43. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195-203.
44. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186:2158-67.
45. Sylvester RJ, Oosterlinck W, Van Der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta Tl bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186-90, quiz 2435.
46. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42:167-74.
47. Dobruch J, Herr H. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int 2009;104:170-4.
48. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709-19.
49. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta Tl urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.
50. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
51. Sylvester RJ, Van Der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
52. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6; discussion 686-687.
53. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
54. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
55. Rodriguez F, Palou J, Martinez R, Rodriguez O, Rosales A, Huguet J et al. [Practical guideline for the management of adverse events associated with BCG installations]. Arch Esp Urol 2008;61:591-6.
56. Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009;1:281-8.
57. Palou J, Rodriguez-Villamil L, Andreu-Crespo A, Salvador-Bayarri J, Vicente-Rodriguez J. Intravesical treatment of severe bacillus Calmette-Guerin cystitis. Int Urol Nephrol 2001;33:485-9.
58. Lamm DL, Van Der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
59. Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 1990;144:1328-30.
60. Patel AR, Sabanegh ES, Jones JS, Gordon SM, Ballin M, Ruggieri PM et al. Bacillus Calmette-Guerin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol 2010;58:934-7.
61. Durek C, Jurczok A, Werner H, Jocham D, Bohle A. Optimal treatment of systemic bacillus Calmette-Guerin infection: investigations in an animal model. J Urol 2002;168:826-31.
62. Falkensammer C, Gozzi C, Hager M, Maier H, Bartsch G, Holtl L et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology 2005;65:175.
63. Mattei FM, Giovannelli V, Schepis L, Del Vecchio MT, Di Renzo M. [Granulomatous prostatitis as collateral effect of intravesical immunotherapy with BCG]. Arch Ital Urol Androl 1998;70:177-82.
64. Beltrami P, Ruggera L, Cazzoletti L, Schiavone D, Zattoni F. Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno-or chemotherapy for superficial bladder cancer? Prostate 2008;68:1241-7.
65. Blah M, Gobet F, Dugardin F, Catovic B, Loisel F, Pfister C. [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?]. Prog Urol 2008;18:108-13.
66. Aust TR, Massey JA. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guerin immunotherapy. Int J Urol 2005;12:920-1.
67. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177:1283-86; discussion 1286.
68. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001.
69. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 2011;60:423-30.
70. Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstadter F et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pTl urothelial bladder cancer. BJU Int 2011;107:404-8.
71. Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R et al. Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pTl Urothelial Bladder Cancer. Eur Urol 2012 [Epub ahead of print].
72. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI et al: Predictive value of combined immunohistochemical markers in patients with pTl urothelial carcinoma at radical cystectomy. J Urol 2009;182:78-84; discussion 84.
73. Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin. Eur Urol 2009;56:829-36.
74. Kramer MW, Waalkes S, Serth J, Hennenlotter J, Tezval H, Stenzl A et al. Decreased galectin-8 is a strong marker for re75.
75. Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, Mansilla F, Sanchez-Carbayo M, Segersten U et al. Cathepsin E, maspin, Plkl, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012;180:1824-34.
76. Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011;60:131-40.
77. Tilki D, Singer BB, Shariat SF, Behrend A, Fernando M, Irmak S et al. CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol 2010;57:648-54.
78. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011;171:5582-92.
79. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34.
80. Orsola A, Cecchini L, Raventos CX, Trilla E, Planas J, Landolfi S et al. Risk factors for positive findings in patients with high-grade Tl bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int 2010;105:202-7.
81. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833-9.
82. Gaya JM, Palou J, Algaba F, Arce J, Rodriguez-Faba O, Villavicencio H. The case for conservative management in the treatment of patients with non-muscleinvasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 2010;17:5370-6.
83. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296-9.
84. Huguet J, Gaya JM, Sabate S, Palou J, Villavicencio H. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy]. Actas Urol Esp 2010;34:63-70.
85. Ghoneim MA, Abdel-Latif M, El-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A et al. Radical cystectomy for carcinoma of the bladder: 2, 720 consecutive cases 5 years later. J Urol 2008;180:121-7.
86. Hautmann RE, Gschwend JE, De Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006;176:486-92; discussion 491-482.
87. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical cystectomy for stages Ta, Tis and Tl transitional cell carcinoma of the bladder. J Urol 1994;151:31-5; discussion 35-36.
88. Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci 2009;40:433-41.
89. Lamm D, Herr H, Jakse G, Kuroda M, Mostofi FK, Okajima E et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998;4:130-8.
90. Lamm DL: Carcinoma in situ. Urol Clin North Am 1992;19:499-508.
91. Sylvester RJ, Van Der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(6 Suppl 1):90-107.
92. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and Tl bladder cancer. BJU Int 2001;88:209-16.
93. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216-23.
94. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials. BJU Int 2004;93:485-90.